UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2023

Gritstone bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-38663 (Commission File Number) 47-4859534 (IRS Employer Identification No.)

5959 Horton Street, Suite 300 Emeryville, California (Address of Principal Executive Offices)

94608

(Zip Code)

Registrant's Telephone Number, Including Area Code: 510 871-6100

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:							
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)						
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)						
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))						
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))						
	Securities registered pursuant to Section 12(b) of the Act:						
		Trading					
	Title of each class	Symbol(s)	Name of each exchange on which registered				
	Common Stock, \$0.0001 par value per share	GRTS	Nasdaq Global Select Market				

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ⊠

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \boxtimes

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 16, 2023, Gritstone bio, Inc. (the "Company") held its 2023 annual meeting of stockholders (the "Annual Meeting"). Only stockholders of record at the close of business on April 19, 2023, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 88,913,562 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 61,122,679 shares of the Company's common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2023.

Proposal No. 1 – Election of Directors

The Company's stockholders elected the Class II director nominees below to the Company's Board of Directors (the "Board") to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected.

Class II Director Nominees	Votes For	Votes Withheld	Broker Non-Votes
Lawrence Corey, M.D.	44,320,684	173,628	16,628,367
Shefali Agarwal, M.D., M.P.H.	30,170,129	14,324,183	16,628,367

Proposal No. 2 - Ratification of Selection of Independent Registered Accounting Firm

The Company's stockholders ratified the selection, by the Audit Committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023.

Votes For	Votes Against	Abstentions	Broker Non-Votes	
60,324,860	649,552	148,267	_	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Gritstone bio, Inc.

Date: June 21, 2023 By: /s/ Andrew Allen

Andrew Allen

President and Chief Executive Officer